I am new to this stock and just come across this article published 13 January 2021 by doctor's from Adelaide.
https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1353-0941
The article conclusion and support from the doctor's is very promising considering TGA decision may come anytime over coming weeks... IMO.
Providing abstract from the article for reference as not sure if it was provided by company before. I am not a doctor or scientist but result highlighted below is promising and if approved by TGA then it holds more hopes to the patients... IMO.
Just note that the article below is good enough for me to invest in this company as achieving in R0 in 4 out 12 itself is promising result IMHO.Abstract
BackgroundThis study evaluated clinical outcomes of combined chemotherapy and endoscopic ultrasound (EUS)-guided intratumoral radioactive phosphorus-32 (32P) implantation in locally advanced pancreatic adenocarcinoma (LAPC).
MethodsConsecutive patients with newly diagnosed LAPC were recruited over 20 months. Baseline computed tomography and18F-2-fluoro-2-deoxy-D-glucose (18FDG) positron emission tomography–computed tomography were performed and repeated after 12 weeks to assess treatment response. Following two cycles of conventional chemotherapy, patients underwent EUS-guided32P implantation followed by six chemotherapy cycles.
Results12 patients with LAPC (median age 69 years [interquartile range 61.5–73.3]; 8 male) completed treatment. Technical success was 100 % with no procedural complications. At 12 weeks, median reduction in tumor volume was 8.2 cm3 (95 % confidence interval 4.95–10.85;P = 0.003), with minimal or no18FDG uptake in nine patients (75 %). Tumor downstaging was achieved in six patients (50 %), leading to successful resection in five (42 %), including four R0 resections (80 %).
Conclusions EUS-guided32P implantation was feasible, well tolerated, and resulted in a 42 % surgical resection rate. Further evaluation in a larger randomized multicenter trial is warranted.
Author Affiliations1 Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia2 School of Health and Medical Sciences, University of Adelaide, Adelaide, AustraliaDylan Bartholomeusz1 Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia2 School of Health and Medical Sciences, University of Adelaide, Adelaide, Australia3 Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, AustraliaJoshua Zobel1 Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, AustraliaRomina Safaeian1 Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, AustraliaWilliam Hsieh3 Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, AustraliaBenjamin Crouch3 Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, AustraliaKaren Ho3 Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, AustraliaDeborah Calnan3 Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, AustraliaNimit Singhal4 Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, AustraliaAndrew Ruszkiewicz2 School of Health and Medical Sciences, University of Adelaide, Adelaide, Australia5 Department of Pathology, Royal Adelaide Hospital, Adelaide, AustraliaJohn W. Chen6 Department of Hepatobiliary Surgery, Royal Adelaide Hospital, Adelaide, AustraliaChuan Ping Tan6 Department of Hepatobiliary Surgery, Royal Adelaide Hospital, Adelaide, AustraliaPaul Dolan6 Department of Hepatobiliary Surgery, Royal Adelaide Hospital, Adelaide, AustraliaNam Q. Nguyen1 Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia2 School of Health and Medical Sciences, University of Adelaide, Adelaide, Australia
GLAH, DYOR
- Forums
- ASX - By Stock
- OSL
- Article Supporting Oncosil Trial
Article Supporting Oncosil Trial
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
-0.001(16.7%) |
Mkt cap ! $16.66M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $2.867K | 573.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 4186862 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 15328756 | 23 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 4186862 | 0.005 |
30 | 24439465 | 0.004 |
6 | 4873298 | 0.003 |
6 | 5457516 | 0.002 |
4 | 7800000 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 15328756 | 23 |
0.007 | 29138909 | 20 |
0.008 | 9343848 | 9 |
0.009 | 12462253 | 5 |
0.010 | 6693666 | 5 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online